194 related articles for article (PubMed ID: 15582885)
21. The role of secondary cytoreductive surgery for recurrent mucinous epithelial ovarian cancer (mEOC).
Cheng X; Jiang R; Li ZT; Tang J; Cai SM; Zhang ZY; Tian WJ; Zang RY
Eur J Surg Oncol; 2009 Oct; 35(10):1105-8. PubMed ID: 19443175
[TBL] [Abstract][Full Text] [Related]
22. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis.
Bristow RE; Puri I; Chi DS
Gynecol Oncol; 2009 Jan; 112(1):265-74. PubMed ID: 18937969
[TBL] [Abstract][Full Text] [Related]
23. Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer.
Santillan A; Karam AK; Li AJ; Giuntoli R; Gardner GJ; Cass I; Karlan BY; Bristow RE
Gynecol Oncol; 2007 Mar; 104(3):686-90. PubMed ID: 17141302
[TBL] [Abstract][Full Text] [Related]
24. Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: a pilot study.
Fagotti A; Paris I; Grimolizzi F; Fanfani F; Vizzielli G; Naldini A; Scambia G
Gynecol Oncol; 2009 Jun; 113(3):335-40. PubMed ID: 19345401
[TBL] [Abstract][Full Text] [Related]
25. Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis.
Harter P; Hahmann M; Lueck HJ; Poelcher M; Wimberger P; Ortmann O; Canzler U; Richter B; Wagner U; Hasenburg A; Burges A; Loibl S; Meier W; Huober J; Fink D; Schroeder W; Muenstedt K; Schmalfeldt B; Emons G; du Bois A
Ann Surg Oncol; 2009 May; 16(5):1324-30. PubMed ID: 19225844
[TBL] [Abstract][Full Text] [Related]
26. Cytoreductive surgery and ovarian carcinoma.
Balbi G; Monteverde A; Landino I; Manganaro MA; Franzese C
Acta Biomed; 2009; 80(3):230-3. PubMed ID: 20578416
[TBL] [Abstract][Full Text] [Related]
27. Recurrent ovarian carcinoma of low malignant potential: the role of secondary surgical cytoreduction and the prognosis in Chinese patients.
Zang RY; Yang WT; Shi DR; Xing Y; Cai SM
J Surg Oncol; 2005 Jul; 91(1):67-72. PubMed ID: 15999350
[TBL] [Abstract][Full Text] [Related]
28. Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer.
Milczek T; Klasa-Mazurkiewicz D; Emerich J; Kobierski J
Acta Obstet Gynecol Scand; 2009; 88(4):463-7. PubMed ID: 19235559
[TBL] [Abstract][Full Text] [Related]
29. Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma.
Helm CW; Randall-Whitis L; Martin RS; Metzinger DS; Gordinier ME; Parker LP; Edwards RP
Gynecol Oncol; 2007 Apr; 105(1):90-6. PubMed ID: 17173957
[TBL] [Abstract][Full Text] [Related]
30. Timing for starting second-line therapy in recurrent ovarian cancer.
Guarneri V; Barbieri E; Dieci MV; Piacentini F; Conte P
Expert Rev Anticancer Ther; 2011 Jan; 11(1):49-55. PubMed ID: 21166510
[TBL] [Abstract][Full Text] [Related]
31. Splenectomy during secondary cytoreduction for ovarian cancer disease recurrence: surgical and survival data.
Manci N; Bellati F; Muzii L; Calcagno M; Alon SA; Pernice M; Angioli R; Panici PB
Ann Surg Oncol; 2006 Dec; 13(12):1717-23. PubMed ID: 16957965
[TBL] [Abstract][Full Text] [Related]
32. Advances in treatment of epithelial ovarian cancer.
Kikkawa F; Nawa A; Ino K; Shibata K; Kajiyama H; Nomura S
Nagoya J Med Sci; 2006 Jan; 68(1-2):19-26. PubMed ID: 16579172
[TBL] [Abstract][Full Text] [Related]
33. The role of secondary cytoreductive surgery for recurrent ovarian cancer.
Güngör M; Ortaç F; Arvas M; Kösebay D; Sönmezer M; Köse K
Gynecol Oncol; 2005 Apr; 97(1):74-9. PubMed ID: 15790440
[TBL] [Abstract][Full Text] [Related]
34. [Feasibility, morbidity and survival of surgery combined with HIPEC in the management of recurrent ovarian cancer].
Furet E; Chéreau E; Lambaudie E; Bannier M; Houvenaeghel G
Gynecol Obstet Fertil; 2013 Sep; 41(9):493-8. PubMed ID: 23972918
[TBL] [Abstract][Full Text] [Related]
35. Role of cytoreductive surgery in recurrent ovarian cancer.
Harter P; Hilpert F; Mahner S; Kommoss S; Heitz F; du Bois A
Expert Rev Anticancer Ther; 2009 Jul; 9(7):917-22. PubMed ID: 19589031
[TBL] [Abstract][Full Text] [Related]
36. Cytoreductive surgery for recurrent ovarian cancer.
Hauspy J; Covens A
Curr Opin Obstet Gynecol; 2007 Feb; 19(1):15-21. PubMed ID: 17218846
[TBL] [Abstract][Full Text] [Related]
37. Cytoreductive surgery and intraoperative hyperthermic chemoperfusion for advanced ovarian carcinoma.
Reichman TW; Cracchiolo B; Sama J; Bryan M; Harrison J; Pliner L; Harrison LE
J Surg Oncol; 2005 May; 90(2):51-6; discussion 56-8. PubMed ID: 15844187
[TBL] [Abstract][Full Text] [Related]
38. Does secondary surgical cytoreduction improve survival in women with advanced ovarian cancer?
Munkarah A
Nat Clin Pract Oncol; 2005 Apr; 2(4):188-9. PubMed ID: 16264930
[No Abstract] [Full Text] [Related]
39. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
Ozols RF
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
[TBL] [Abstract][Full Text] [Related]
40. Intraoperative radiation therapy in recurrent ovarian cancer.
Yap OW; Kapp DS; Teng NN; Husain A
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1114-21. PubMed ID: 15964710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
